These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30120626)

  • 1. Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?
    Langlois MR; Nordestgaard BG
    Curr Cardiol Rep; 2018 Aug; 20(10):88. PubMed ID: 30120626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
    Langlois MR; Nordestgaard BG; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
    Clin Chem Lab Med; 2020 Mar; 58(4):496-517. PubMed ID: 31855562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Nordestgaard BG; Langlois MR; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
    Atherosclerosis; 2020 Feb; 294():46-61. PubMed ID: 31928713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
    Langlois MR; Chapman MJ; Cobbaert C; Mora S; Remaley AT; Ros E; Watts GF; Borén J; Baum H; Bruckert E; Catapano A; Descamps OS; von Eckardstein A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard BG;
    Clin Chem; 2018 Jul; 64(7):1006-1033. PubMed ID: 29760220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
    März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW
    Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How to manage lipid profiles and their interpretation in patients with coronary heart disease?].
    Farnier M
    Presse Med; 2009 Jun; 38(6):958-63. PubMed ID: 19376680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
    Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2011 Jul; 108(1):40-6. PubMed ID: 21565322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
    Meyer BJ; Hammervold T; Rustan AC; Howe PR
    Lipids; 2007 Mar; 42(2):109-15. PubMed ID: 17393216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
    Nordestgaard BG; Langsted A; Mora S; Kolovou G; Baum H; Bruckert E; Watts GF; Sypniewska G; Wiklund O; Borén J; Chapman MJ; Cobbaert C; Descamps OS; von Eckardstein A; Kamstrup PR; Pulkki K; Kronenberg F; Remaley AT; Rifai N; Ros E; Langlois M;
    Eur Heart J; 2016 Jul; 37(25):1944-58. PubMed ID: 27122601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
    Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO
    Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein B assessment for evaluating lipid goals.
    Tekiner E; Oguz A; Uzunlulu M; Tekiner F
    Acta Cardiol; 2011 Aug; 66(4):433-8. PubMed ID: 21894798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.